Sai Life Sciences Limited , a leading Contract Research, Development and Manufacturing (CRDMO) company, has reported robust financial results for the first quarter, demonstrating significant growth across key metrics.

Financial Highlights

The company's consolidated revenue from operations surged to Rs. 4,964.19 crore in Q1, marking a substantial increase from Rs. 2,797.23 crore in the corresponding quarter of the previous year. This impressive growth of 77.47% underscores the company's strong market position and expanding client base.

Profit after tax (PAT) showed a remarkable turnaround, with the company reporting a consolidated PAT of Rs. 604.55 crore, compared to a loss of Rs. 134.98 crore in the same quarter last year. This significant improvement in profitability reflects the company's operational efficiency and successful execution of its business strategies.

On a standalone basis, Sai Life Sciences reported equally impressive results:

The company's earnings per share (EPS) also showed substantial improvement, with consolidated basic EPS rising to Rs. 2.90, up from a loss per share of Rs. 0.74 in the corresponding quarter of the previous year.

Operational Performance

The strong financial performance can be attributed to the company's focus on its core CRDMO segment. Sai Life Sciences has been successful in leveraging its expertise in contract research, development, and manufacturing services, catering to the growing demands of the pharmaceutical and biotechnology industries.

Leadership Continuity

In a move that signals confidence in the current leadership, the Board of Directors has approved the reappointment of Mr. Krishnamraju Kanumuri as Managing Director & CEO for another five-year term, effective from September 1, 2025. This reappointment is subject to shareholder approval at the upcoming Annual General Meeting (AGM).

Corporate Updates

The company has scheduled its 26th Annual General Meeting for September 11, 2025, which will be conducted via video conferencing, in line with modern corporate practices and considering potential ongoing health precautions.

Outlook

With a strong start to the fiscal year and strategic leadership continuity, Sai Life Sciences appears well-positioned to capitalize on the growing opportunities in the global CRDMO market. The company's ability to turn around its profitability and achieve significant revenue growth demonstrates its resilience and adaptability in a dynamic industry landscape.

Sai Life Sciences , a leading global Contract Research, Development & Manufacturing Organization (CRDMO), witnessed significant block deals as private equity firm TPG sold a substantial portion of its stake in the company.

Major Stake Sale

TPG, a global investment firm, divested over 2 crore shares of Sai Life Sciences at Rs 722.00 per share. The total value of the stake sale amounted to approximately Rs 1,505.00 crore, marking a notable transaction in the pharmaceutical sector.

Key Buyers

The stake sale attracted interest from both international and domestic investors:

• Norges Bank, the central bank of Norway, acquired 11.5 lakh shares of Sai Life Sciences.
• Several Indian mutual funds participated in the block deal, including:
  • Nippon India Mutual Fund
  • Invesco Mutual Fund
  • Aditya Birla Sun Life Mutual Fund

This diverse set of buyers indicates strong institutional interest in the company.

Market Response

The market reacted positively to the news of the block deals:

• Sai Life Sciences' stock rallied by 5% following the transaction.
• The shares closed at Rs 765.85 on the Bombay Stock Exchange (BSE).

The uptick in share price suggests that investors view the change in ownership structure and the entry of new institutional investors as a positive development for the company.

About Sai Life Sciences

Sai Life Sciences is a contract research, development, and manufacturing organization (CRDMO) that provides services to the pharmaceutical industry. The company specializes in drug discovery, development, and manufacturing services, supporting global innovators in bringing new medicines to market faster.

The recent block deals and the subsequent stock rally highlight the company's strong position in the pharmaceutical services sector and investor confidence in its future prospects.